A U.S. Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo Nordisk covering the active ingredient in its weight-loss and diabetes drugs Wegovy and Ozempic brought ...

Novo Nordisk said on Monday the U.S. Food and Drug Administration (FDA) had approved its therapy to treat a rare genetic condition that affects the kidneys.

Danish drugmaker Novo Nordisk aims to bring its blockbuster weight-loss drug Wegovy to India in 2026, after securing regulatory approvals and ensuring it has enough supply to meet demand, a top com...

Novo Nordisk has the income flow to pay a dividend for the long term. It also has a pipeline full of candidates to keep the growth going.

Ozempic, Wegovy and other diabetes/weight loss drugs were prescribed more than 9 million times in the US during the fourth quarter of 2022, according to a new report.  A Trilliant Health analysis o...

Novo Nordisk (NYSE:NVO)'s stellar growth is unlikely to slow this year, according to Stifel, which was updating its views after a call with the Danish pharma's management. “Our main takeaway is tha...

Novo Nordisk (NVO) collaborates with Valo Health to discover and develop novel treatments for cardiometabolic diseases using Valo's proprietary drug development platform.

Denmark's Novo Nordisk (NVO) struck a deal with U.S.-based health tech firm Valo Health to use artificial intelligence (AI) to discover and develop treatments for cardiometabolic diseases such as h...

Morgan Stanley (NYSE:MS) expects the EU biopharma sector to offer a safe haven from weakening growth/higher real yields. “Whilst we continue to favour growth/innovation narratives in biopharma over...

Novo Nordisk (NYSE:NVO) has announced a collaboration with Valo Health to discover and develop novel treatments for cardiometabolic using Valo's artificial intelligence (AI)-powered Opal Computatio...

Novo Nordisk NVO, +0.01% on Monday announced a partnership with Valo Health Inc., a technology company specializing in AI-powered drug discovery and development, to focus on new cardiometabolic dru...

Revenue is up 29% this year as Wegovy and Ozempic have been in high demand. Sales could go even higher as the company sorts out manufacturing issues.

An analyst reiterated his recommendation and price target. Unfortunately, that recommendation is the equivalent of a sell.

The company inked yet another supply deal with a European healthcare tech specialist. Also, an analyst reiterated his buy recommendation on the Wegovy maker.

Danish diabetes care giant Novo Nordisk is splitting its shares, with the Danish-listed B shares splitting on September 13 and the NYSE-listed ADRs splitting on September 20. This split marks a mil...